Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Jeswin Joseph

3PUBLICATIONS
8CO-AUTHORS
Nanoscale characterisationGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

Sort by Publication Date:
|Aug 01, 2025
Lumazine Synthase Nanoparticles as a Versatile Platform for Multivalent Antigen Presentation and Cross-Protective Coronavirus Vaccines.

Jeswin Joseph, Kavitha Modenkattil Sethumadhavan, Priyanca Ahlawat

|Mar 13, 2023
SARS-CoV-2 neutralizing antibody epitopes are overlapping and highly mutated which raises the chances of escape variants and requires development of broadly reactive vaccines.

Jeswin Joseph, Sukhada Darpe, Grishma Kulkarni

|Aug 07, 2021
SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling.

Thankamani Karthika, Jeswin Joseph, V R Akshay Das

Pageof 1

Frequent Collaborators

3 joint publications

V Stalin Raj

1 joint publications

Thankamani Karthika

1 joint publications

V R Akshay Das

1 joint publications

Niranjana Nair

1 joint publications

Packirisamy Charulekha

1 joint publications

Melvin Daniel Roji

1 joint publications

Kavitha Modenkattil Sethumadhavan

1 joint publications

Reji Varghese

Frequent Collaborators

3 joint publications

V Stalin Raj

1 joint publications

Thankamani Karthika

1 joint publications

V R Akshay Das

1 joint publications

Niranjana Nair

Top Related Videos

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on : Jul 25, 2022

2.7K
Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on : Aug 29, 2017

11.8K
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on : Mar 01, 2019

59.3K
See more related videos

Top Related Videos

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on : Jul 25, 2022

2.7K
Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on : Aug 29, 2017

11.8K
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on : Mar 01, 2019

59.3K
See more related videos